Vertex Hepatitis C Drug Gets FDA OK
CAMBRIDGE (CBS/AP) -- The Food and Drug Administration has approved the hepatitis C drug from Cambridge-based Vertex Pharmaceuticals. Incivek is a highly-anticipated pill, from patients and investors alike.
Vertex launched a nationwide campaign to increase awareness of hepatitis C, expecting the FDA approval. Incivek could be available in pharmacies later this week.
WBZ NewsRadio 1030's Anthony Silva reports.
Podcast
Incivek is expected to generate billions of dollars in annual sales. Vertex says a 12-week course of treatment will cost $49,200, compared to $30,000 for standard therapies.
Vertex executive Vice President Nancy Wysenski said this will be the company's first product.
(TM and © Copyright 2011 CBS Radio Inc. and its relevant subsidiaries. CBS RADIO and EYE Logo TM and Copyright 2011 CBS Broadcasting Inc. Used under license. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed. The Associated Press contributed to this report.)
